uniQure (NASDAQ:QURE) Shares Cross Above 50 Day Moving Average – What’s Next?

uniQure N.V. (NASDAQ:QURE)’s stock price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $35.02 and traded as high as $41.92. uniQure shares last traded at $39.70, with a volume of 1,070,189 shares changing hands.

Analyst Upgrades and Downgrades

QURE has been the subject of several recent research reports. The Goldman Sachs Group increased their target price on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Royal Bank Of Canada upped their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Leerink Partners raised their price objective on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. HC Wainwright lifted their target price on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $25.00 to $65.00 in a report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $64.17.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -11.60 and a beta of 0.90. The stock’s fifty day moving average price is $35.24 and its 200-day moving average price is $25.34.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities research analysts predict that uniQure N.V. will post -3.56 EPS for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 164,429 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares in the company, valued at $24,766,459.20. This represents a 22.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $431,228.16. Following the completion of the sale, the insider directly owned 108,864 shares of the company’s stock, valued at $2,945,859.84. This trade represents a 12.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 433,229 shares of company stock valued at $17,944,799 in the last ninety days. Corporate insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fulton Bank N.A. acquired a new position in shares of uniQure in the second quarter worth $220,000. Hennion & Walsh Asset Management Inc. boosted its position in uniQure by 107.3% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock valued at $6,546,000 after purchasing an additional 73,566 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in uniQure by 249.9% during the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock valued at $23,653,000 after purchasing an additional 366,781 shares during the last quarter. Militia Capital Management LLC purchased a new position in uniQure in the first quarter valued at about $1,540,000. Finally, Flax Pond Capital LLC increased its position in uniQure by 3.8% in the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock worth $2,486,000 after purchasing an additional 5,533 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.